Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 0.74 |
| ▸ | RAB9A | P51151 | 13/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.74 |
| ▸ | TP53 | P04637 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | PKM | P14618 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149341 | 0.81 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL3596544 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL3597396 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL3596550 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL1353243 | 0.78 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL16148074 | 0.78 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL30786728 | 0.76 | KMT2A (0.75) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4141992 | 0.76 | KMT2A (0.75) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5934413 | 0.76 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL14157012 | 0.76 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | NPC1 1234/4885RAB9A 1701/4885SMN1; SMN2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.